Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock price drop, with a decline exceeding 70% following a notification from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value to support continued listing [1][2]. Group 1: Company Announcement and Stock Performance - On November 14, 2025, the company received a letter from the Stock Exchange indicating that it failed to maintain sufficient operational levels and asset value, leading to a decision to suspend trading of its shares on November 26, 2025 [2][3]. - The company had previously announced a failed placement agreement to issue up to 145 million shares at HKD 0.415 per share, as the conditions precedent were not met by September 11, 2025 [1][3]. Group 2: Financial Performance - For the fiscal year ending March 31, 2025, the company reported a revenue of HKD 2.091 million, a year-on-year decrease of 68.28%, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [5]. - The basic earnings per share for the reporting period were -HKD 0.2001, with net cash flow from operating activities at -HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [5].

Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock crash, with a drop exceeding 70% due to regulatory actions from the Hong Kong Stock Exchange regarding its operational viability and asset value [2][5][9]. Company Announcement - On November 14, 2025, Starcoin Group received a notification from the Hong Kong Stock Exchange stating that it failed to maintain sufficient operational levels and asset value, leading to a suspension of its shares on November 26, 2025, unless a review is requested [4][6]. - The company announced that a planned share placement of up to 145 million shares at HKD 0.415 per share has become void due to unmet conditions by September 11, 2025, terminating all responsibilities between the placement agent and the company [2][7]. Financial Performance - For the fiscal year ending March 31, 2025, Starcoin Group reported a revenue of HKD 2.091 million, a decline of 68.28% year-on-year, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [10]. - The basic earnings per share for the reporting period was -HKD 0.2001, with a net cash outflow from operating activities of HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [10]. Company Background - Starcoin Group operates in the pharmaceutical and biotechnology sector, with five divisions including genetic testing services, bioproduct distribution, beauty equipment trade, securities investment, and research on oral insulin products [9]. - The company had previously seen a significant stock price increase of nearly 100% during June to July 2025 before entering a downward trend [9].

Market Overview - A-shares exhibited mixed performance with major indices showing limited volatility on July 2 [1][3] - The marine economy concept stocks surged, becoming one of the strongest sectors in the A-share market, with the sector overall rising over 6% [3] Sector Performance - Leading sectors included engineering machinery, non-ferrous metals, trade agency, shipbuilding, steel, and home appliances, while sectors such as components, communication equipment, semiconductors, and software services saw declines [3] Marine Economy Development - The Central Financial and Economic Commission emphasized the importance of high-quality development in the marine economy, focusing on innovation, efficient collaboration, and industry updates [5] - Key initiatives include enhancing marine technology innovation, fostering leading marine technology enterprises, and promoting sustainable marine industry growth [5] Hong Kong Market Highlights - The Hong Kong market performed well, with the Hang Seng Index rising over 1% at one point, and individual stocks like Galaxy Entertainment and Sands China leading with gains exceeding 7% [6] - Notably, the stock of Leading Pharmaceutical Biotechnology experienced a dramatic increase, with a peak rise of over 200% during trading [6] Acquisition Announcement - Leading Pharmaceutical Biotechnology announced a memorandum of understanding regarding a potential acquisition, which involves acquiring the entire equity of a target company contingent upon the completion of asset acquisition from Conflux [8] - The acquisition aims to diversify the company's revenue sources and expand into the digital innovation sector, particularly blockchain technology [9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃由本公司自願作出。 董事會欣然宣佈，於二零二五年六月三十日（聯交所交易時段後），本公司（作 為買方）已與賣方及Conflux訂立諒解備忘錄，內容有關收購目標公司全部股 權的潛在收購事項，前提為目標公司按照與本公司的協議完成收購Conflux 資產。 潛在收購事項須待本公司與賣方訂立正式協議後方可作實。因此，潛在收 購事項未必會進行。本公司將根據上市規則適時刊發公告。股東及本公司 潛在投資者於買賣本公司股份時務請審慎行事。 – 1 – INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 自願公告 有關潛在收購事項的 諒解備忘錄 緒言 董事會欣然宣佈，於二零二五年六月三十日（聯交所交易時段後），本公司（作 為買方）已與賣方及Conflux訂立諒解備忘錄，內容有關潛在 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代 號：399） 自願公告 有關潛在合作的 諒解備忘錄 本公告乃由本公司自願作出。 董事會欣然宣佈，於二零二五年五月六日（聯交所交易時段後），本公司已與 Conflux訂立諒解備忘錄，內容有關本公司有意就Conflux區塊鏈的相關基礎設 施及共通關鍵技術與Conflux深入合作，包括但不限於創新技術研發、應用場 景探索及潛在股權合作。 潛在合作須待本公司與Conflux訂立正式協議後方可作實。因此，潛在合作可 能或未必會進行。本公司將根據上市規則適時刊發公告。股東及本公司潛在 投資者於買賣本公司股份時務請審慎行事。 – 1 – INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） 緒言 茲提述本公司日期為二零二五年四月二十五日之公告，內容有關本公司擬擴 充業務至區塊鏈技術。 董事會欣然宣佈 ...